Reemergence of JAK2 V617F clone heralds extramedullary leukemia relapse after BMT for transformed essential thrombocytosis

Au, Wing Y.; Fung, A.; Lam, K Y; Lam, Clk; Kwong, Yok–Lam

doi:10.1007/s00277-006-0213-2

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A potential confounding factor of this qPCR approach is the possibility of clonal evolution in which the JAK2 V617F relinquishes its role as the main driving mutation of this disease. While early detection of extramedullary relapse of AML cases using residual disease monitoring of AML-associated genetic markers has been documented, evidence for a similar benefit in JAK2 V617F-positive PMF, particularly after ASCT, is scarce [ 18 – 20 ].…”

Section: Discussionmentioning

confidence: 99%

Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation ofJAK2V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation

Langabeer

Nolan

Haslam

et al. 2015

Case Reports in Hematology

View full text Add to dashboard Cite

Monitoring of the JAK2 V617F allele burden in myeloproliferative neoplasms after allogeneic stem cell transplantation is useful to determine levels of residual disease and has the potential to detect early relapse and guide subsequent clinical intervention. A case is described of a JAK2 V617F-positive primary myelofibrosis patient who underwent allogeneic stem cell transplantation. Prospective residual disease monitoring of the peripheral blood failed to detect an extramedullary manifestation of the disease, a periorbital myeloid sarcoma, arising nearly three years after transplant. This case serves to highlight a pitfall in residual disease monitoring for myeloproliferative neoplasm-associated mutations in the post-allogeneic stem cell transplantation setting.

show abstract

Section: Discussionmentioning

confidence: 99%